There are B-ALL subtypes, such as KMT2A-rearranged ALL, that have lower CD22 expression and poorer response to Inotuzumab, but it remains unclear whether this directly related to CD22 expression (Jabbour et al., 2019). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.